Here's Why Ventas Stock is an Apt Portfolio Pick for Now
Rising senior citizens' population and favorable outpatient visit trends are likely to benefit VTR.
Ventas: Growth Set To Continue In The Years Ahead
Ventas is a healthcare REIT focused on senior housing, outpatient medical & research, and triple-net lease properties. The Q3 2024 results were solid and the company increased its normalized FFO midpoint outlook. With a valuation above private market alternatives and distressed peers, Ventas is tapping debt and equity markets to grow its portfolio and increase normalized FFO.
Ventas, Inc. (VTR) Q3 2024 Earnings Call Transcript
Ventas, Inc. (VTR) Q3 2024 Earnings Call Transcript
Ventas' Q3 FFO Meet Estimates on Higher Same-Store NOI, View Raised
VTR's Q3 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.
Here's What Key Metrics Tell Us About Ventas (VTR) Q3 Earnings
Although the revenue and EPS for Ventas (VTR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ventas (VTR) Q3 FFO Match Estimates
Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.80 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.75 per share a year ago.
Healthcare REIT Ventas raises annual FFO per share forecast
Healthcare REIT Ventas slightly raised the lower end of its annual funds from operations (FFO) forecast on Wednesday, expecting continued strong performance from its assisted living and senior housing properties.
Stay Ahead of the Game With Ventas (VTR) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Ventas (VTR) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
What's in the Offing for Ventas Stock This Earnings Season?
VTR's Q3 earnings are likely to have benefited from favorable SHOP operating trends, healthy demand for life-science real estate assets and accretive investments.
1 High-Yield Dividend Stock to Buy and 1 to Avoid
I've been holding on to this dividend-paying REIT, but there is a better option out there if you have new money to put to work.
Ventas Stock Rises 48.9% in Six Months: What You Should Know
VTR is poised to gain from a favorable demand in senior housing, backed by an expected rise in senior citizens' population.
Ventas Secures Agreements With Kindred & ScionHealth for 23 LTACs
To improve patient care facilities, VTR announces reaching an agreement with Kindred and ScionHealth regarding 23 long-term acute care hospitals.
